Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer
receiving anthracyclines - de Baat, EC - 2022 | Cochrane Library Skip to Content Cookies Our …

In both cardiovascular disease and cancer, there are established sex-based differences in
prevalence and outcomes. Males and females may also differ in terms of risk of cardiotoxicity …

The population of patients with cancer is rapidly expanding, and the diagnosis and
monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in …

There are nearly 17 million cancer survivors in the United States, including those who are
currently receiving cancer therapy with curative intent and expected to be long-term …

Over the last decades, childhood and adolescence have emerged as an important window
of opportunity to prevent atherosclerotic cardiovascular disease (ASCVD) later in life. Here …

Oncology has seen growing use of newly developed targeted therapies. Although this has
resulted in dramatic improvements in progression-free and overall survival, challenges in …

An important priority in the cardiovascular care of oncology patients is to reduce morbidity
and mortality, and improve the quality of life in cancer survivors through cross-disciplinary …

Background Cardiotoxicity is among the most important adverse effects of childhood cancer
treatment. Anthracyclines, mitoxantrone and radiotherapy involving the heart are its main …

Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for many
malignancies, hemoglobinopathies, metabolic diseases, bone marrow failure syndromes …

Background Cardiomyopathy is a leading cause of late morbidity and mortality in childhood
cancer survivors (CCS). Evidence-based guidelines recommend risk-stratified screening for …